# A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06926920/  
OnCo record `nct06926920` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sacituzumab govitecan in triple-negative breast cancer, run by Gilead Sciences, now recruiting.

## Summary

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06926920 by Gilead Sciences, with 100 participants planned, started 2025-04-30 and due to reach its primary completion in 2028-06. Interventions recorded: Sacituzumab Govitecan-hziy (SG).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06926920
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Sponsor: Gilead Sciences
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06926920: https://clinicaltrials.gov/study/NCT06926920

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct06926920.json